Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 543980 | NSE: JLHL | Hospital & Healthcare Services | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Jupiter Life Line Hospitals Ltd is a good quality company.
The key valuation ratios of Jupiter Life Line Hospitals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Jupiter Life Line Hospitals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 16% | 23.1% | 16.6% | 11.4% | 10.7% | 7.9% | 9.9% | 7.2% | 18% | 18.1% | - |
| Value Creation Index ⓘ | 0.2 | 0.7 | 0.2 | -0.2 | -0.2 | -0.4 | -0.3 | -0.5 | 0.3 | 0.3 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 186 | 222 | 251 | 264 | 320 | 399 | 463 | 461 | 657 | 787 | 787 |
| Sales YoY Gr. | - | 19.3% | 13% | 5.4% | 21.3% | 24.4% | 16.2% | -0.4% | 42.6% | 19.8% | - |
| Adj EPS ⓘ | 3.3 | 6.5 | 6.2 | 5.8 | 5.9 | 3.6 | 5.8 | 3.3 | 16.6 | 19.2 | 16.4 |
| YoY Gr. | - | 99.1% | -4.9% | -6.8% | 1.6% | -39.5% | 63.5% | -44% | 409.2% | 15.7% | - |
| BVPS (₹) ⓘ | 16.4 | 22.8 | 27.9 | 33.7 | 39 | 41.9 | 46.5 | 49.8 | 64.3 | 82.3 | 183.5 |
| Adj Net Profit ⓘ | 16.4 | 32.7 | 31.1 | 29.3 | 29.9 | 18.1 | 29.6 | 16.6 | 84.5 | 109 | 107 |
| Cash Flow from Ops. ⓘ | 34.2 | 45.9 | 49.9 | 62.7 | 43.5 | 45.6 | 74.6 | 113 | 142 | 183 | - |
| Debt/CF from Ops. ⓘ | 2.3 | 1.8 | 2.3 | 3 | 4.8 | 5.5 | 3.5 | 2.3 | 2.3 | 1.6 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 17.4% | 19.7% | 19.4% | 19.8% | ||||
| Adj EPS ⓘ | 21.7% | 26.7% | 48.9% | 15.7% | ||||
| BVPSⓘ | 19.6% | 16.1% | 20.9% | 28% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 23.8 | 35.9 | 25.3 | 18.9 | 16.2 | 8.8 | 13.2 | 6.8 | 29 | 27.4 | 12.3 |
| Op. Profit Mgn % ⓘ | 21.9 | 27.3 | 24.4 | 23.3 | 17 | 16.3 | 17.6 | 14.6 | 24.2 | 25.9 | 24.6 |
| Net Profit Mgn % ⓘ | 8.8 | 14.7 | 12.4 | 11.1 | 9.3 | 4.5 | 6.4 | 3.6 | 12.9 | 13.8 | 13.6 |
| Debt to Equity ⓘ | 1 | 0.8 | 0.8 | 1.1 | 1.1 | 1.2 | 1.1 | 1 | 1 | 0.6 | - |
| Working Cap Days ⓘ | 53 | 53 | 53 | 50 | 54 | 65 | 88 | 91 | 54 | 62 | 43 |
| Cash Conv. Cycle ⓘ | -74 | -52 | -37 | -42 | -41 | -28 | -29 | -36 | -35 | -33 | 31 |
Sales growth is growing at healthy rate in last 3 years 19.36%
Net Profit is growing at healthy rate in last 3 years 48.89%
Debt to equity has declined versus last 3 years average to 0.64
Sales growth is good in last 4 quarters at 11.53%
Return on Equity has declined versus last 3 years average to 12.30%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 16.4 | 11.1 |
| TTM Sales (₹ Cr.) | 787 | 893 |
| BVPS (₹.) ⓘ | 183.5 | 171.5 |
| Reserves (₹ Cr.) ⓘ | 1,137 | 1,059 |
| P/BV ⓘ | 6.59 | 7.05 |
| PE ⓘ | 73.95 | 108.76 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 960.00 / 1648.60 |
| All Time Low / High (₹) | 960.00 / 1648.60 |
| Market Cap (₹ Cr.) | 7,929 |
| Equity (₹ Cr.) | 65.6 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 84.6 |
| Pledged * | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 186 | 222 | 251 | 264 | 320 | 399 | 463 | 461 | 657 | 787 |
| Operating Expenses ⓘ | 145 | 161 | 189 | 203 | 266 | 334 | 382 | 394 | 498 | 583 |
| Manufacturing Costs | 12 | 12 | 15 | 17 | 23 | 51 | 61 | 56 | 67 | 81 |
| Material Costs | 41 | 44 | 49 | 50 | 60 | 81 | 80 | 94 | 127 | 135 |
| Employee Cost | 26 | 31 | 37 | 43 | 67 | 82 | 93 | 100 | 114 | 129 |
| Other Costs ⓘ | 66 | 74 | 88 | 93 | 116 | 120 | 148 | 143 | 190 | 238 |
| Operating Profit ⓘ | 41 | 61 | 61 | 62 | 54 | 65 | 81 | 68 | 159 | 204 |
| Operating Profit Margin (%) | 21.9% | 27.3% | 24.4% | 23.3% | 17.0% | 16.3% | 17.6% | 14.6% | 24.2% | 25.9% |
| Other Income ⓘ | 1 | 2 | 2 | 3 | 5 | 3 | 3 | 6 | 4 | 13 |
| Interest ⓘ | 12 | 10 | 8 | 8 | 16 | 24 | 26 | 28 | 29 | 28 |
| Depreciation ⓘ | 9 | 10 | 11 | 12 | 20 | 24 | 26 | 27 | 28 | 29 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 |
| Profit Before Tax ⓘ | 21 | 43 | 45 | 45 | 24 | 20 | 33 | 18 | 106 | 159 |
| Tax ⓘ | 5 | 10 | 14 | 15 | -6 | 2 | 3 | 1 | 21 | 52 |
| Profit After Tax | 16 | 33 | 31 | 29 | 30 | 18 | 30 | 17 | 85 | 107 |
| PAT Margin (%) | 8.8% | 14.7% | 12.4% | 11.1% | 9.3% | 4.6% | 6.4% | 3.6% | 12.9% | 13.6% |
| Adjusted EPS (₹) | 3.5 | 7.0 | 6.2 | 5.8 | 5.9 | 3.6 | 5.8 | 3.3 | 16.7 | 19.0 |
| Dividend Payout Ratio (%) | 14% | 7% | 8% | 9% | 9% | 28% | 0% | 0% | 6% | 5% |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 76 | 106 | 140 | 170 | 198 | 213 | 237 | 253 | 327 | 465 |
| Share Capital ⓘ | 46 | 47 | 50 | 51 | 51 | 51 | 51 | 51 | 51 | 57 |
| Reserves ⓘ | 30 | 60 | 90 | 120 | 147 | 162 | 186 | 202 | 276 | 409 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 71 | 75 | 104 | 180 | 197 | 241 | 254 | 250 | 319 | 295 |
| Long Term Debt | 46 | 54 | 88 | 177 | 186 | 234 | 244 | 258 | 298 | 295 |
| Short Term Debt | 24 | 20 | 16 | 3 | 11 | 7 | 10 | -9 | 21 | 0 |
| Trade Payables | 21 | 20 | 18 | 28 | 37 | 37 | 59 | 50 | 54 | 62 |
| Others Liabilities ⓘ | 26 | 30 | 37 | 41 | 38 | 45 | 44 | 63 | 55 | 63 |
| Total Liabilities ⓘ | 194 | 231 | 298 | 420 | 470 | 537 | 594 | 615 | 755 | 885 |
Fixed Assets | ||||||||||
| Gross Block | 196 | 202 | 224 | 319 | 471 | 547 | 576 | 595 | 660 | 700 |
| Accumulated Depreciation | 40 | 50 | 61 | 73 | 93 | 116 | 141 | 168 | 195 | 224 |
| Net Fixed Assetsⓘ | 156 | 151 | 163 | 246 | 379 | 431 | 435 | 426 | 465 | 476 |
| CWIP ⓘ | 9 | 37 | 92 | 132 | 28 | 12 | 11 | 13 | 14 | 16 |
| Investmentsⓘ | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 65 | 71 | 95 |
| Inventories | 5 | 5 | 6 | 6 | 10 | 10 | 14 | 12 | 13 | 15 |
| Trade Receivables | 8 | 12 | 12 | 13 | 18 | 26 | 45 | 20 | 28 | 40 |
| Cash Equivalents | 1 | 4 | 6 | 3 | 4 | 8 | 7 | 19 | 102 | 133 |
| Others Assetsⓘ | 14 | 21 | 18 | 17 | 31 | 48 | 81 | 59 | 62 | 108 |
| Total Assets ⓘ | 194 | 231 | 298 | 420 | 470 | 537 | 594 | 615 | 755 | 885 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 34 | 46 | 50 | 63 | 43 | 46 | 75 | 113 | 142 | 183 |
| PBT ⓘ | 21 | 43 | 45 | 45 | 24 | 20 | 33 | 18 | 106 | 159 |
| Adjustment ⓘ | 22 | 19 | 19 | 18 | 31 | 45 | 66 | 54 | 54 | 48 |
| Changes in Working Capital ⓘ | -4 | -7 | -2 | 9 | -0 | -5 | -9 | 51 | -9 | -4 |
| Tax Paid ⓘ | -5 | -6 | -8 | -9 | -11 | -14 | -15 | -10 | -9 | -20 |
| Cash Flow From Investing Activity ⓘ | -11 | -34 | -76 | -133 | -43 | -58 | -43 | -78 | -69 | -59 |
| Capex | -11 | -35 | -77 | -135 | -48 | -60 | -29 | -22 | -66 | -43 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 1 | 0 | -57 | -5 | -23 |
| Others ⓘ | 0 | 1 | 1 | 2 | 5 | 1 | -15 | 1 | 2 | 7 |
| Cash Flow From Financing Activityⓘ | -24 | -9 | 28 | 68 | 1 | 16 | -32 | -23 | 10 | -93 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 5 | 2 | 1 | 0 | 0 | 0 | 2 | 34 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 47 | 7 | 18 | 31 | -3 |
| Interest Paid ⓘ | -12 | -10 | -8 | -8 | -16 | -24 | -26 | -28 | -29 | -28 |
| Dividend Paid ⓘ | 0 | -2 | 84 | -3 | -3 | -3 | -5 | 0 | 0 | -5 |
| Others ⓘ | -13 | 3 | -53 | 77 | 18 | -4 | -9 | -13 | 7 | -91 |
| Net Cash Flow ⓘ | -1 | 3 | 2 | -3 | 1 | 3 | -1 | 12 | 84 | 31 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 23.8 | 35.86 | 25.3 | 18.89 | 16.23 | 8.82 | 13.17 | 6.77 | 29.18 | 27.07 |
| ROCE (%) | 21.34 | 30.74 | 23.94 | 17.19 | 10.42 | 9.95 | 12.14 | 9.01 | 23.15 | 26.4 |
| Asset Turnover Ratio | 0.96 | 1.04 | 0.95 | 0.74 | 0.72 | 0.79 | 0.82 | 0.76 | 0.96 | 0.96 |
| PAT to CFO Conversion(x) | 2.13 | 1.39 | 1.61 | 2.17 | 1.43 | 2.56 | 2.5 | 6.65 | 1.67 | 1.71 | Working Capital Days |
| Receivable Days | 20 | 16 | 17 | 17 | 18 | 20 | 28 | 26 | 13 | 16 |
| Inventory Days | 9 | 8 | 8 | 8 | 9 | 9 | 10 | 10 | 7 | 7 |
| Payable Days | 225 | 170 | 141 | 167 | 196 | 167 | 219 | 210 | 149 | 157 |
Jupiter Life Line Hospitals was incorporated in Mumbai, Maharashtra, as ‘Jupiter Life Line Hospitals Limited’, a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 18, 2002, issued by the RoC. The company commenced its business on December 24, 2002. The company is among the key multi-specialty tertiary and quaternary healthcare providers in the Mumbai Metropolitan Area (MMR) and western region of India. It has been operating for many years as a corporate quaternary care healthcare service provider in densely populated micro markets in the western regions of India and currently operate three hospitals under the ‘Jupiter’ brand in Thane, Pune and Indore. It is also currently in the process of developing a multi-specialty hospital in Dombivli, Maharashtra, which is designed to accommodate many beds.
The company commenced operations in 2007 with its hospital in Thane, Maharashtra and subsequently scaled its operations by setting up a hospital in Pune, Maharashtra in 2017 and acquiring a hospital in Indore, Madhya Pradesh in 2020. Its hospitals are also located in densely populated micro markets which have a low presence of chained hospitals, which provides it an opportunity to offer its services to a larger population and helps its patients with greater access and connectivity to healthcare services. Its hospitals function on an ‘all-hub-no-spoke’ model with each hospital being a full-service hospital, operating independently and serving the healthcare needs of patients, right from diagnostics to surgery and rehabilitation. Its Thane and Pune hospitals are ‘greenfield’ projects, and all three of its hospitals are located on land owned by it on a freehold basis, which ensures operational control and allows it consistency in quality care resulting in long-term operational and financial efficiencies.
Business area of the company
The company is engaged in the business of operating and managing hospitals and clinics in India. The company is among the key multi-specialty tertiary and quaternary healthcare providers.
Awards
Accreditations and recognitions
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
